Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17958889 | 1.00 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL6834854 | 1.00 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL30590044 | 1.00 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL23152976 | 0.90 | ALDH1A1 (0.37) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL20756448 | 0.90 | ALDH1A1 (0.37) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL25400002 | 0.89 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL25400006 | 0.89 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL25400372 | 0.89 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL1098278 | 0.89 | ALDH1A1 (0.42) | ALDH1A1LMNAPRKCACYP2D6MAPK1 | |
| SCHEMBL30689531 | 0.89 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCACYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | ALDH1A1 996/4885LMNA 2780/4885PRKCA 2782/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | ALDH1A1 1897/4885LMNA 2417/4885PRKCA 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.